ESMO25 Breast Cancer Highlights: DESTINY-Breast11 & DESTINY-Breast05 | Dana-Farber Cancer Institute

15 Visioni

  • Grazie! Condividilo con i tuoi amici!

    Non hai gradito questo video. Grazie per il feedback!

admin
Published
Harold Burstein, MD, PhD, and Guilherme Nader Marta, MD, discuss the DESTINY-Breast11 and DESTINY-Breast05 trials examining trastuzumab deruxtecan in HER2-positive breast cancer, which were presented at ESMO 2025.

For more information about Dana-Farber's Breast Oncology Center, visit https://www.dana-farber.org/cancer-care/treatment/breast-oncology
Categoria
Oncology
Commenta per primo questo video.

Prossimo